A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Tropifexor (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 06 Sep 2018 Status changed from recruiting to completed.
- 11 Aug 2018 The study has been discontinued in Germany.
- 25 Jun 2018 Planned End Date changed from 18 Feb 2020 to 17 Mar 2020.